• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BSEM
Share

BioStem Technologies, Inc. Stocks

$ 3.7Last Updated 23.06.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 66.10M

$ 3.7
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

25.02.2025 16:59

Zacks recommends small-cap drugmaker BioStem that has sunk 30% in three weeks

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioStem Technologies, Inc. is a life sciences company committed to the research, creation, and production of pharmaceutical and regenerative medical treatments and services. The firm primarily develops diverse alternative biological products, largely derived from stem cells, aimed at addressing ailments such as joint pain, injuries to tendons and ligaments, as well as neurodegenerative and autoimmune conditions. Additionally, BioStem Technologies is involved in the repackaging and distribution of active pharmaceutical ingredients and other supplies essential for pharmaceutical compounding. The company also designs and sells nutraceutical products, including its proprietary lines like Dr. Dave's Best and Nesvik Organics, along with other non-branded items, distributing them across the United States and globally. Its sales operations predominantly leverage e-commerce platforms. Established in 2006, BioStem Technologies, Inc. maintains its operational base in Pompano Beach, Florida.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of BSEM is 7.0 and suggests 79.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

24.06.2026 01:09

The Nasdaq fell 2%, with volatility hitting a two-year high: a look back at the day's sell-off in the tech sector

24.06.2026 00:50

The dollar rose to its highest level since November: Traders are betting on a Fed rate hike

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026